A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in a phase ... A rapidly developed, dual-target chimeric antigen receptor T-cell ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

In addition to leukemia, CAR-T cells are now used to treat other blood cancers, including multiple myeloma and some kinds of lymphoma ... we've found a molecular target we can investigate to ...

Researchers have developed an innovative dual ... cells. However, while CAR T-cells have shown great promise for the treatment of blood cancers, they have struggled to effectively target solid ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...